1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Biosimilars Forum Sees Lessons Being Learned From US Humira Experience

Executive Director Julie Reed Says Low Uptake For Adalimumab Has Gained Attention

 
• By Dave Wallace

In an interview with Generics Bulletin, Julie Reed, executive director of the US Biosimilars Forum, says that the low uptake for Humira rivals in the US has “raised everyone’s attention to what is going on and what is wrong with the system.”

Meter with low reading
Uptake has so far been low for Humira biosimilars in the US • Source: Shutterstock

The low uptake seen for Humira (adalimumab) biosimilars in the first year of US competition has focused people’s minds on the weaknesses of the country’s biosimilars framework, Biosimilars Forum executive director Julie Reed has told Generics Bulletin in an exclusive interview.

But despite obstacles to uptake for biosimilars in the US, the industry association remains optimistic that policy-makers and stakeholders will look at the roadblocks and address some of the more suboptimal

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.